ZA200703746B - MRNA ratios in urinary sediments and/or urine as a prognostic and/or theranostic marker for prostate cancer - Google Patents

MRNA ratios in urinary sediments and/or urine as a prognostic and/or theranostic marker for prostate cancer

Info

Publication number
ZA200703746B
ZA200703746B ZA200703746A ZA200703746A ZA200703746B ZA 200703746 B ZA200703746 B ZA 200703746B ZA 200703746 A ZA200703746 A ZA 200703746A ZA 200703746 A ZA200703746 A ZA 200703746A ZA 200703746 B ZA200703746 B ZA 200703746B
Authority
ZA
South Africa
Prior art keywords
prostate cancer
value
ratio
psa
amount
Prior art date
Application number
ZA200703746A
Other languages
English (en)
Inventor
Hessels Daphne
Verhaegh Gerald
Jack A Schalken
Alfred J Witjes
Original Assignee
Stichting Katholieke Univ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stichting Katholieke Univ filed Critical Stichting Katholieke Univ
Publication of ZA200703746B publication Critical patent/ZA200703746B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96455—Kallikrein (3.4.21.34; 3.4.21.35)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
ZA200703746A 2004-12-24 2007-05-09 MRNA ratios in urinary sediments and/or urine as a prognostic and/or theranostic marker for prostate cancer ZA200703746B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002491067A CA2491067A1 (en) 2004-12-24 2004-12-24 Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer

Publications (1)

Publication Number Publication Date
ZA200703746B true ZA200703746B (en) 2008-07-30

Family

ID=36636708

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200703746A ZA200703746B (en) 2004-12-24 2007-05-09 MRNA ratios in urinary sediments and/or urine as a prognostic and/or theranostic marker for prostate cancer

Country Status (12)

Country Link
US (8) US7960109B2 (https=)
EP (3) EP2226394B1 (https=)
JP (1) JP4944041B2 (https=)
AT (1) ATE457362T1 (https=)
AU (1) AU2005318369B2 (https=)
CA (2) CA2491067A1 (https=)
DE (1) DE602005019294D1 (https=)
DK (1) DK1761651T3 (https=)
ES (2) ES2340513T3 (https=)
IL (1) IL183476A0 (https=)
WO (1) WO2006066965A2 (https=)
ZA (1) ZA200703746B (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
JP3981416B2 (ja) * 1997-04-10 2007-09-26 ユニバーシティ メディカル センター ナイメーヘン Ｐｃａ３タンパク質、ｐｃａ３遺伝子、及びこれらの用途
PT1222266E (pt) * 1999-09-29 2006-07-31 Diagnocure Inc Arn mensageiro de pca3 em tecidos benignos e malignos da prostata
AU2004209578A1 (en) 2003-02-07 2004-08-19 Diagnocure Inc. Method to detect prostate cancer in a sample
US11105808B2 (en) 2004-11-12 2021-08-31 Health Discovery Corporation Methods for screening, predicting and monitoring prostate cancer
CA2491067A1 (en) 2004-12-24 2006-06-24 Stichting Katholieke Universiteit Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer
WO2007109321A2 (en) 2006-03-20 2007-09-27 The Regents Of The University Of California Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
JP4943074B2 (ja) * 2006-07-03 2012-05-30 シスメックス株式会社 がん転移の判定方法及び装置
US8940298B2 (en) 2007-09-04 2015-01-27 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection
US20090226912A1 (en) * 2007-12-21 2009-09-10 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with prostate cancer risk
GB2465088C (en) * 2008-10-30 2016-01-27 Caris Mpi Inc miRNA expression in the characterisation and classification of cancer
EP2358912B1 (en) * 2008-10-30 2016-10-12 Caris Life Sciences Switzerland Holdings GmbH Methods for assessing rna patterns
GB2463401B (en) * 2008-11-12 2014-01-29 Caris Life Sciences Luxembourg Holdings S A R L Characterizing prostate disorders by analysis of microvesicles
WO2011109440A1 (en) 2010-03-01 2011-09-09 Caris Life Sciences Luxembourg Holdings Biomarkers for theranostics
EP2398504B1 (en) 2009-02-17 2018-11-28 Cornell Research Foundation, Inc. Methods and kits for diagnosis of cancer and prediction of therapeutic value
JP2010233542A (ja) * 2009-03-31 2010-10-21 Kanazawa Univ Ｒａｇｅ遺伝子の２種類のスプライシングバリアントを区別して増幅可能なプライマーセット及びプローブ
EP2320235A1 (en) 2009-11-06 2011-05-11 IMG Institut für medizinische Genomforschung Planungsgesellschaft M.B.H. Marker for prostate cancer diagnosis
EP2320234A1 (en) 2009-11-06 2011-05-11 IMG Institut für medizinische Genomforschung Planungsgesellschaft M.B.H. Marker combination for prostate cancer diagnosis
CA2782333C (en) 2009-12-02 2019-06-04 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
WO2011127219A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease
BR112012026322B1 (pt) * 2010-04-16 2020-10-27 Hunter Douglas Inc. processo de fabricação de uma persiana corrediça com ripas
WO2012031207A2 (en) 2010-09-03 2012-03-08 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with prostate cancer risk
ES2541054T3 (es) * 2010-10-20 2015-07-15 Université De Bordeaux Firmas del resultado clínico en tumores estromales gastrointestinales y método de tratamiento de tumores estromales gastrointestinales
US9534256B2 (en) 2011-01-06 2017-01-03 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with risk of aggressive prostate cancer
EP3492606B1 (en) * 2011-08-22 2023-10-04 Exosome Diagnostics, Inc. Urine biomarkers
EP2574929A1 (en) 2011-09-28 2013-04-03 IMG Institut für medizinische Genomforschung Planungsgesellschaft M.B.H. Marker in diagnosing prostate cancer (PC)
AU2014305994B2 (en) * 2013-08-06 2019-02-21 Exosome Diagnostics, Inc. Urine biomarker cohorts, gene expression signatures, and methods of use thereof
US10364469B2 (en) 2014-01-16 2019-07-30 Illumina, Inc Gene expression panel for prognosis of prostate cancer recurrence
US9994912B2 (en) 2014-07-03 2018-06-12 Abbott Molecular Inc. Materials and methods for assessing progression of prostate cancer
CN107250375A (zh) 2014-11-06 2017-10-13 科罗拉多州立大学董事会 在血栓溶解剂存在下使用粘弹性分析鉴定新疾病状态
US11187710B2 (en) 2015-06-08 2021-11-30 The Regents Of The University Of Colorado, A Body Corporate Time independent viscoelastic analysis parameter for prediction of patient outcome
WO2017027325A1 (en) 2015-08-07 2017-02-16 Imaginab, Inc. Antigen binding constructs to target molecules
WO2017091640A1 (en) 2015-11-24 2017-06-01 The Johns Hopkins University Raman spectroscopy reporters and methods for molecular imaging of tissue in vivo
EP3455366A4 (en) 2016-05-11 2020-02-26 Michael P. Chapman ANALYSIS OF VISCOELASTICITY IN PATIENTS WITH A DISEASE ASSOCIATED WITH THE CARDIOVASCULAR SYSTEM
WO2017194668A1 (en) * 2016-05-13 2017-11-16 Roche Diagnostics Gmbh Detection of met exon 14 deletions and associated therapies
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies
CN111655833A (zh) * 2017-11-13 2020-09-11 株式会社理光 检测判断装置
WO2019169336A1 (en) * 2018-03-02 2019-09-06 The Johns Hopkins University Methods for prostate cancer detection
CN110423797A (zh) * 2019-07-11 2019-11-08 杨海涛 一种前列腺癌pca3基因双重实时pcr的引物、方法及试剂盒
CN114743593B (zh) * 2022-06-13 2023-02-24 北京橡鑫生物科技有限公司 一种基于尿液进行前列腺癌早期筛查模型的构建方法、筛查模型及试剂盒

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2422956A1 (fr) * 1978-04-13 1979-11-09 Pasteur Institut Procede de detection et de caracterisation d'un acide nucleique ou d'une sequence de celui-ci, et reactif enzymatique pour la mise en oeuvre de ce procede
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4690890A (en) 1984-04-04 1987-09-01 Cetus Corporation Process for simultaneously detecting multiple antigens using dual sandwich immunometric assay
US4786600A (en) * 1984-05-25 1988-11-22 The Trustees Of Columbia University In The City Of New York Autocatalytic replication of recombinant RNA
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
JPS63501765A (ja) 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング　インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4851331A (en) * 1986-05-16 1989-07-25 Allied Corporation Method and kit for polynucleotide assay including primer-dependant DNA polymerase
FR2602592B1 (fr) 1986-08-06 1989-06-30 Alain Baret Utilisation du systeme enzymatique xanthine-oxydase en immuno-analyse, procedes de dosage correspondants et coffrets de reactifs necessaires pour la mise en oeuvre de ces procedes.
US5541308A (en) 1986-11-24 1996-07-30 Gen-Probe Incorporated Nucleic acid probes for detection and/or quantitation of non-viral organisms
US5202231A (en) 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
US5149625A (en) 1987-08-11 1992-09-22 President And Fellows Of Harvard College Multiplex analysis of DNA
US5585481A (en) * 1987-09-21 1996-12-17 Gen-Probe Incorporated Linking reagents for nucleotide probes
US5283174A (en) 1987-09-21 1994-02-01 Gen-Probe, Incorporated Homogenous protection assay
US5639604A (en) 1987-09-21 1997-06-17 Gen-Probe Incorporated Homogeneous protection assay
AU622426B2 (en) 1987-12-11 1992-04-09 Abbott Laboratories Assay using template-dependent nucleic acid probe reorganization
US5002867A (en) * 1988-04-25 1991-03-26 Macevicz Stephen C Nucleic acid sequence determination by multiple mixed oligonucleotide probes
NL8801147A (nl) 1988-05-02 1989-12-01 Tno Werkwijze voor het detecteren van genetische variatie, en daarvoor geschikte kit.
DK167254B1 (da) 1988-07-21 1993-09-27 Hartmann As Brdr Fremgangsmaade til fremstilling af formede genstande af et fluidiseret cellulosefibermateriale
US5183949A (en) * 1988-09-22 1993-02-02 The United States Of America As Represented By The Department Of Health And Human Services Rabbit model for diagnosing and testing vaccines or therapeutic agents against aids
US5118801A (en) 1988-09-30 1992-06-02 The Public Health Research Institute Nucleic acid process containing improved molecular switch
US5219989A (en) * 1988-12-13 1993-06-15 Mcgill University Bifunctional protein for the isolation of capped mRNA
US5082670A (en) * 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
US5175383A (en) * 1989-02-17 1992-12-29 President And Fellows Of Harvard College Animal model for benign prostatic disease
US5112736A (en) * 1989-06-14 1992-05-12 University Of Utah Dna sequencing using fluorescence background electroblotting membrane
US5656207A (en) * 1989-06-24 1997-08-12 Gen Probe Incorporated Detecting or quantifying multiple analytes using labelling techniques
US5174986A (en) * 1989-07-05 1992-12-29 Genpharm International, Inc. Method for determining oncogenic potential of a chemical compound
CA2020958C (en) 1989-07-11 2005-01-11 Daniel L. Kacian Nucleic acid sequence amplification methods
IE911869A1 (en) 1990-06-01 1991-12-04 Regeneron Pharma A family of map2 protein kinases
AU662906B2 (en) 1991-06-26 1995-09-21 F. Hoffmann-La Roche Ag Methods for detection of carcinoma metastases by nucleic acid amplification
CA2082411A1 (en) * 1991-06-28 1992-12-29 Robert D. Rosenberg Localized oligonucleotide therapy
WO1993003743A1 (en) 1991-08-16 1993-03-04 The General Hospital Corporation Method of gene delivery to post-mitotic cells
AU3129993A (en) 1991-11-08 1993-06-07 Massachusetts Institute Of Technology Localized oligonucleotide therapy
WO1993012236A1 (en) * 1991-12-16 1993-06-24 E.I. Du Pont De Nemours And Company Constitutive expression of p450soy and ferredoxin-soy in streptomyces, and biotransformation of chemicals by recombinant organisms
KR940703846A (ko) 1991-12-24 1994-12-12 비. 린네 파샬 갭(gap)이 형성된 2′ 변성된 올리고뉴클레오티드(gapped 2′ modifed oligonucleotides)
JP4137996B2 (ja) * 1992-05-06 2008-08-20 ジェン−プローブ・インコーポレイテッド 核酸配列増幅方法，組成物及びキット
US5674682A (en) 1992-10-29 1997-10-07 Thomas Jefferson University Nucleic acid primers for detecting micrometastasis of prostate cancer
ES2276390T3 (es) 1992-11-05 2007-06-16 Sloan-Kettering Institute For Cancer Research Antigeno de membrana especifico de la prostata.
US5503980A (en) 1992-11-06 1996-04-02 Trustees Of Boston University Positional sequencing by hybridization
US5773705A (en) * 1992-12-31 1998-06-30 Wisconsin Alumni Research Foundation Ubiquitin fusion protein system for protein production in plants
ATE208634T1 (de) 1993-01-07 2001-11-15 Univ Jefferson Modulation der proliferation von glatten muskelzellen durch antisense inhibition von c-myc
US5422252A (en) * 1993-06-04 1995-06-06 Becton, Dickinson And Company Simultaneous amplification of multiple targets
US5861242A (en) 1993-06-25 1999-01-19 Affymetrix, Inc. Array of nucleic acid probes on biological chips for diagnosis of HIV and methods of using the same
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US6323184B1 (en) 1993-10-15 2001-11-27 Thomas Jefferson University Arteriovenous and venous graft treatments: methods and compositions
US5925517A (en) * 1993-11-12 1999-07-20 The Public Health Research Institute Of The City Of New York, Inc. Detectably labeled dual conformation oligonucleotide probes, assays and kits
WO1995025180A1 (en) * 1994-03-16 1995-09-21 Gen-Probe Incorporated Isothermal strand displacement nucleic acid amplification
CA2187775A1 (en) 1994-04-15 1995-10-26 Aaron E. Katz Method for molecular staging of prostate cancer
US6169169B1 (en) 1994-05-19 2001-01-02 Dako A/S PNA probes for detection of Neisseria gonorrhoeae and Chlamydia trachomatis
AU3889595A (en) 1994-10-05 1996-05-02 Amgen, Inc. Method for inhibiting smooth muscle cell proliferation and oligonucleotides for use therein
EP0709466B1 (en) 1994-10-28 2006-09-27 Gen-Probe Incorporated Compositions and methods for the simultaneous detection and quantification of multiple specific nucleic acid sequences
US5919652A (en) 1994-11-09 1999-07-06 The Regents Of The University Of California Nucleic acid molecules comprising the prostate specific antigen (PSA) promoter and uses thereof
DE19513152A1 (de) * 1995-04-07 1996-10-10 Bundesrep Deutschland Verwendung eines "Immundefizienzvirus-supprimierenden Lymphokins (ISL)" zur Hemmung der Virusvermehrung, insbesondere von Retroviren
US5731148A (en) 1995-06-07 1998-03-24 Gen-Probe Incorporated Adduct protection assay
WO1998002582A2 (en) 1996-07-16 1998-01-22 Gen-Probe Incorporated Methods for detecting and amplifying nucleic acid sequences using modified oligonucleotides having increased target specific t¿m?
US6479263B1 (en) * 1996-11-14 2002-11-12 Baylor College Of Medicine Method for detection of micrometastatic prostate cancer
US6465611B1 (en) * 1997-02-25 2002-10-15 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6261562B1 (en) * 1997-02-25 2001-07-17 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
TR199902053T2 (xx) * 1997-02-25 2000-04-21 Corixa Corporation Prostat kanserinin immunoterapisine y�nelik bile�ikler ve bunlar�n kullan�lmas�na matuf metodlar.
US6800746B2 (en) * 1997-02-25 2004-10-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6395278B1 (en) * 1997-02-25 2002-05-28 Corixa Corporation Prostate specific fusion protein compositions
JP3981416B2 (ja) * 1997-04-10 2007-09-26 ユニバーシティ メディカル センター ナイメーヘン Ｐｃａ３タンパク質、ｐｃａ３遺伝子、及びこれらの用途
DE69836012T2 (de) 1997-05-02 2007-04-05 Gen-Probe Inc., San Diego Zwei-schritt hybridisierung und einfang von einem polynukleotid
US6534273B2 (en) 1997-05-02 2003-03-18 Gen-Probe Incorporated Two-step hybridization and capture of a polynucleotide
EP0986562B1 (en) * 1997-05-08 2002-08-07 MERCK SHARP & DOHME LTD. Substituted 1,2,4-triazolo 3,4-a]phthalazine derivatives as gaba alpha 5 ligands
AU7703998A (en) * 1997-05-30 1998-12-30 Lxr Biotechnology Inc. Methods for detection of nucleic acid sequences in urine
US20020035244A1 (en) * 1997-09-09 2002-03-21 Maurice Cohen Reagents and methods useful for detecting diseases of the prostate
US6124120A (en) 1997-10-08 2000-09-26 Yale University Multiple displacement amplification
US6200765B1 (en) * 1998-05-04 2001-03-13 Pacific Northwest Cancer Foundation Non-invasive methods to detect prostate cancer
CN100419079C (zh) 1998-07-14 2008-09-17 科里克萨有限公司 用于治疗和诊断前列腺癌的组合物和方法
US6037130A (en) * 1998-07-28 2000-03-14 The Public Health Institute Of The City Of New York, Inc. Wavelength-shifting probes and primers and their use in assays and kits
CA2360073C (en) * 1999-01-28 2011-01-18 Gen-Probe Incorporated Probes and primers for detecting prostate specific antigen (psa) in a biological sample
FI990382A0 (fi) 1999-02-23 1999-02-23 Arctic Partners Oy Ab Uusi diagnostinen menetelmä
US6528260B1 (en) * 1999-03-25 2003-03-04 Genset, S.A. Biallelic markers related to genes involved in drug metabolism
ATE466938T1 (de) 1999-03-26 2010-05-15 Jackson H M Found Military Med Prostata-spezifisches gen pcgem1 und methoden zu dessen verwendung zur erkennung, behandlung und prävention von prostatakrebs
PT1222266E (pt) * 1999-09-29 2006-07-31 Diagnocure Inc Arn mensageiro de pca3 em tecidos benignos e malignos da prostata
AU7994200A (en) 1999-10-04 2001-05-10 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
AU7859900A (en) 1999-10-04 2001-05-10 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
EP1230364A2 (en) 1999-11-12 2002-08-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
CN1398301B (zh) 1999-12-17 2011-03-23 比奥美希奥公司 标记核酸的方法
IL150732A0 (en) 2000-01-14 2003-02-12 Corixa Corp Prostate specific polypeptides, polynucleotides that encode said polypeptides and pharmaceutical compositions containing the same
US20020168638A1 (en) * 2000-01-24 2002-11-14 Robert Schlegel Compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
WO2001060860A2 (en) 2000-02-17 2001-08-23 Millennium Predictive Medicine, Inc. Genes differentially expressed in human prostate cancer and their use
CA2403909A1 (en) 2000-03-27 2001-10-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
FR2810114B1 (fr) 2000-06-13 2002-08-23 Bio Merieux Methode, procede, test immunologique et kit de diagnostic d'un adenocarcinome de la prostate ou d'une hypertrophie benigne de la prostate
US20030031678A1 (en) 2000-09-19 2003-02-13 Shujath Ali Compositions and methods relating to prostate specific genes and proteins
AU2002215345A1 (en) 2000-10-13 2002-04-22 Eos Biotechnology, Inc. Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
US6897024B2 (en) * 2001-05-31 2005-05-24 Stichting Katholieke Universiteit More Particularly The University Medical Centre Nijmegen Nucleic acid molecules comprising the promoter for PCA3, and uses thereof
AU2004209578A1 (en) * 2003-02-07 2004-08-19 Diagnocure Inc. Method to detect prostate cancer in a sample
CA2432365A1 (en) 2003-06-30 2004-12-30 Jack A. Schalken Specific method of prostate cancer detection based on pca3, and kits therefore
CA2491067A1 (en) * 2004-12-24 2006-06-24 Stichting Katholieke Universiteit Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer

Also Published As

Publication number Publication date
DK1761651T3 (da) 2010-05-17
HK1148315A1 (en) 2011-09-02
US20100021884A1 (en) 2010-01-28
IL183476A0 (en) 2007-09-20
WO2006066965A2 (en) 2006-06-29
JP2008524998A (ja) 2008-07-17
US20130261171A1 (en) 2013-10-03
US20160362746A1 (en) 2016-12-15
CA2491067A1 (en) 2006-06-24
US20120309007A1 (en) 2012-12-06
US9951390B2 (en) 2018-04-24
US8257924B2 (en) 2012-09-04
US20120003640A1 (en) 2012-01-05
CA2594125A1 (en) 2006-06-29
EP1761651A2 (en) 2007-03-14
EP2226394B1 (en) 2015-06-03
EP2325334A1 (en) 2011-05-25
ES2546193T3 (es) 2015-09-21
US20180223375A1 (en) 2018-08-09
US20150307948A1 (en) 2015-10-29
CA2594125C (en) 2016-06-14
EP1761651B1 (en) 2010-02-10
US20200392588A1 (en) 2020-12-17
ATE457362T1 (de) 2010-02-15
US9096907B2 (en) 2015-08-04
EP2226394A1 (en) 2010-09-08
JP4944041B2 (ja) 2012-05-30
DE602005019294D1 (de) 2010-03-25
WO2006066965A3 (en) 2006-10-26
ES2340513T3 (es) 2010-06-04
AU2005318369A1 (en) 2006-06-29
US10752957B2 (en) 2020-08-25
AU2005318369B2 (en) 2012-02-09
US7960109B2 (en) 2011-06-14

Similar Documents

Publication Publication Date Title
ZA200703746B (en) MRNA ratios in urinary sediments and/or urine as a prognostic and/or theranostic marker for prostate cancer
WO2006113747A3 (en) Diagnostic markers of breast cancer treatment and progression and methods of use thereof
WO2006012646A3 (en) Amacr cancer markers
AU2010217160B2 (en) Method for detecting metastasis of GI cancer
WO2004076679A3 (en) Serum macrophage migration inhibitory factor (mif) as marker for prostate cancer
Righi et al. Galectin-3 expression in pituitary adenomas as a marker of aggressive behavior
WO2007056192A3 (en) Composite profiles of cell antigens and target signal transduction proteins for analysis and clinical management of hematologic cancers
WO2007093657A2 (es) Método para el diagnóstico molecular de cáncer de próstata y kit para implementar el método
WO2006036788A3 (en) Methods and compositions for evaluating breast cancer prognosis
WO2002061128A3 (en) Method of determining a chemotherapeutic regimen based on ercc1 expression
JP2008524998A5 (https=)
Zehentner et al. Detection of α-methylacyl-coenzyme-A racemase transcripts in blood and urine samples of prostate cancer patients
WO2009103790A3 (en) Method and kit for the detection of genes associated with pik3ca mutation and involved in pi3k/akt pathway activation in the er-positive and her2-positive subtypes with clinical implications
Yang et al. Overexpression of HMGA2 in bladder cancer and its association with clinicopathologic features and prognosis: HMGA2 as a prognostic marker of bladder cancer
WO2008001357A3 (en) Methods and kits for diagnosing cancer
WO2002064015A8 (en) Pin1 as a marker for prostate cancer
WO2007048076A3 (en) Method for the diagnosis and prognosis of cancer
Miyake et al. Significance of micrometastases in pelvic lymph nodes detected by real‐time reverse transcriptase polymerase chain reaction in patients with clinically localized prostate cancer undergoing radical prostatectomy after neoadjuvant hormonal therapy
WO2009087689A4 (en) Novel primers for identification of astrocytoma, it's grades and glioblastoma prognosis
WO2008116178A8 (en) Systems and methods for diagnosis and prognosis of colorectal cancer
ATE394676T1 (de) Verbindungen und verfahren zur diagnose von prostatakrebs
WO2005113835A3 (en) Kits and methods for indentification, assessment, prevention and therapy of breast cancer
WO2008086502A3 (en) Molecular marker for clear renal cell carcinoma
Schostak et al. Kinetic fluorescence reverse transcriptase-polymerase chain reaction for alpha-methylacyl CoA racemase distinguishes prostate cancer from benign lesions
Luscombe et al. Glutathione S-transferase GSTP1 genotypes are associated with response to androgen ablation therapy in advanced prostate cancer